Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
licaminlimab · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| licaminlimab | EXPERIMENTAL | 60 mg/mL licaminlimab ophthalmic solution |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of licaminlimab ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Artificial Tear Run-in | OTHER | Artificial tear eye drop run-in three times daily (TID) for approximately 14 days. |
| licaminlimab | DRUG | Licaminlimab eye drops three times daily (TID) for 29 days. |
| Vehicle of licaminlimab | OTHER | Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days. |
| vehicle of OCS-02 | OTHER | inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks. |
| Artificial tears | OTHER | Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days. |
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere ...
Top 20 of 25 competitors